Targeting Complement Activation in Antineutrophil Cytoplasmic Autoantibodies (ANCA)-Vasculitis - Eculizumab
Status:
Withdrawn
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this research study is to see if Eculizumab (Soliris®) can safely be used in
addition to conventional therapy in patients with active ANCA (Antineutrophil Cytoplasmic
Autoantibodies ) vasculitis and lead to a more rapid decrease in disease activity.
ANCA vasculitis is an inflammation of the small vessels whereby ANCA antibodies
inappropriately activate one's own white blood cells (neutrophils) and cause damage to the
small blood vessels.
Phase:
Phase 2
Details
Lead Sponsor:
University of North Carolina, Chapel Hill
Collaborators:
Alexion Pharmaceuticals National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) National Institutes of Health (NIH)
Treatments:
Autoantibodies Complement System Proteins Eculizumab